Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is something big happening on Monday during the shareholder meeting?
2 chainz - "Pull up to the scene with my ceiling missing"
What does this mean? It sounds great!!
NASDQ announcement coming soon. Frost's investment proves it.
In a week Facebook likes have gone up nearly 10,000!
Stop it. You have no idea about their Payables.
No company ever pays up front. That would not make business sense to pay for something before you receive it.
Summary of Statements of Operations
Year Ended December 31 Three Months Ended March 31
2012 2011 2013 2012
(Unaudited)
Sales – Net $ 67,055,215 $ 17,212,636 $ 22,561,227 $ 16,560,680
Loss from operations $ (8,735,811 ) $ (16,220,160 ) $ (721,480 ) $ (727,293 )
Other expense $ (10,216,984 ) $ (7,060,790 ) $ (6,640,501 ) $ (15,308,000 )
Net loss $ (18,952,795 ) $ (23,280,950 ) $ (7,368,049 ) $ (16,035,293 )
Net loss per common share-basic diluted $ (13.00 ) $ (70.30 ) $ (1.78 ) $ (11.23 )
Weighted average number of common shares outstanding – basic and diluted 1,458,757 331,158 4,128,679 1,428,024
Statement of Financial Position
As of March 31
2013
Cash $ 8,482,927
Total Assets $ 20,537,257
Current Liabilities $ 13,309,425
Long-Term Debt $ 506
Stockholders’ equity $ 7,227,326
8
You don't know they are having payment problems and neither do I. Stop pretending you know. You aren't fooling anyone.
This company is on the verge of making a profit this year and expanding international exposure and increasing revenue. And people are worried about a retirement plan for this company. Give me a break.
Muscle Pharm wouldn't be in business if they have continued to do this. You obviously do not understand business.
Royal Oak?
SA Article
The Market Believes Muscle Pharm Will Continue To Grow
10:20 AM ET | by MTF Investing | About: MSLP.OB
Whenever I see an increase in the number of articles written for a company, I remain skeptical of pumping and dumping scenarios. So when I started to see an increase in the articles about a relatively small company that participated in the Sports Nutrition sector, I decided to take a look. It also didn't hurt that I was familiar with the company and enjoy going to the gym. Muscle Pharm (MSLP.OB) is a fitness supplement that is part of the estimated $91.8 Billion Sports Nutrition sector. Since being founded in 2008, sales have risen from $1 Million in 2009 to $78 Million in 2012.
When looking at a company, there are a few questions I generally ask myself. How's the management team? Do they produce a quality product? What is a fair price for the company?
How's the management team?
Brad Pyatt is the CEO and Founder of Muscle Pharm. As a former NFL football wide receiver, he understands the sports industry, and has access to some of the top athletes and teams in the industry. He also understands what athletes look for in a brand and supplement, and more importantly, how to advertise to athletes. He has also been able to find valuable sponsors for Muscle Pharm that will reach younger populations, like the Ultimate Fighting Championship and the recent addition of Colin Kaepernick of the San Francisco 49ers.
Cory Gregory is the co-founder and current Executive Vice President. He also knows the business, and has been part of the fitness sector since collage; opening a gym and competing in weight lifting events. While he doesn't have the NFL career of Pyatt, he is still respected in the training room, and practices what he preaches.
While there are other members of the management team, these two have placed the company squarely in front of their targeted audience. Financially, the company is on solid ground. They have paid off almost all debt, and finally are turning a profit.
How does the company look?
Muscle Pharm is a well-respected company within the health and fitness sector. Their recent addition to in store placement in 24 Hour Fitness will help to boost sales, but their online success is a testament to their popularity. BodyBuilding.com, a top site for fitness enthusiasts, lists their top 50 products. Optimum has the most products on the list with 12, but Muscle Pharm is right behind them with 11, representing 22% of the top 50. On muscleandstrength.com they represent 8 of the top 50. While revenues and profitability will vary based on margins, for a company competing in the $91.8 Billion industry, grabbing 11-8 of the top 50 spots positions it well to claim a portion of the pie.
What is a fair price?
Even a great company can be overpriced, and a poor company can be too cheap to pass up. In looking for a fair price for the stock, I took into account a few things.
What is the expected growth of the company? They obviously cannot sustain an explosive growth, but they can probably ride out their success for the next couple years until growth normalizes. Over the past four quarters they went from $2.4M to $4M, stayed constant at $4M, and then doubled again to $8M. This represents a 400% increase over the year. The addition of the 24 Hour Fitness will help to keep growth, but I wanted to also look at something more sustainable. In preparing the chart, I looked at growth from 10% - 200%.
Revenue Growth Rate (yearly) 2012 2013 2014 2015 2016
10% 67,055 73,761 81,137 89,250 98,175
20% 67,055 80,466 96,559 115,871 139,045
30% 67,055 87,172 113,323 147,320 191,516
40% 67,055 93,877 131,428 183,999 257,598
50% 67,055 100,583 150,874 226,311 339,466
60% 67,055 107,288 171,661 274,657 439,452
70% 67,055 113,994 193,789 329,441 560,050
80% 67,055 120,699 217,258 391,065 703,917
90% 67,055 127,405 242,069 459,930 873,867
100% 67,055 134,110 268,220 536,440 1,072,880
120% 67,055 147,521 324,546 714,002 1,570,804
140% 67,055 160,932 386,237 926,968 2,224,724
160% 67,055 174,343 453,292 1,178,559 3,064,253
180% 67,055 187,754 525,711 1,471,991 4,121,576
200% 67,055 201,165 603,495 1,810,485 5,431,455
How will they capitalize on tax structures and margins? The charts were prepared using EBIT of 15% and 20% and a tax rate of 38% and 25%.
Revenue Growth Rate (yearly) Justified Stock Price (EBIT = 15%, tax rate = 38%) Justified Stock Price (EBIT = 20%, tax rate = 38%) Justified Stock Price (EBIT = 20%, tax rate = 25%)
10% $0.75 $0.83 $0.83
20% $1.04 $1.15 $1.15
30% $1.43 $1.57 $1.57
40% $1.92 $2.09 $2.09
50% $2.54 $2.74 $2.74
60% $3.30 $3.55 $3.55
70% $4.23 $4.53 $4.53
80% $5.36 $5.71 $5.71
90% $6.59 $5.94 $6.34
100% $6.53 $5.85 $6.85
120% $7.74 $8.18 $9.84
140% $10.71 $11.27 $13.84
160% $14.58 $15.30 $19.07
180% $19.54 $20.46 $25.77
200% $25.79 $26.96 $34.25
Based on the math, it looks like the market believes growth will be around 140% until 2016, which is possible with this stock and in this market. That represents revenues in the neighborhood of $2 Billion.
Other considerations
Muscle Pharm is still listed on the OTC market, but has been applying for admittance to one of the major exchanges. Once they are picked up by a major exchange, it will open them up to fund managers, increasing potential volume and price.
Muscle Pharm still in an aggressive growth phase, and I believe they may still see aggressive growth beyond the 200% the analysis is based on. Right now they represent less than .1% of the $91 Billion industry. As they continue to promote their product thru additional endorsements they will see revenue and market share continue to increase.
Conclusion
Muscle Pharm has gained popularity in the gym and on the trading floor. They have a solid management team that understands the industry and the customer. Customers like they product and consistently return to it, increasing market share. The market has priced the company based on potential growth of about 140% over the next four years, a very real possibility. I believe that once the company is listed on a major stock exchange, the increase in visibility and volume will drive the price even higher.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
I'm out.
Same here in Detroit. Two sold.
I believe that volume is low because everyone is waiting for news about being in all Walgreens and for revenue info. I think they will be in all Walgreens next week and revs will be much higher in the 10q in Aug. Fuse will trickle up by August.
Awesome increase in revenue. Once the 10q is released this will tick up
How did you come up with that estimate?
$1.20
300% sounds great but I believe they need a 1000% increase. I hope they can succeed. Im waiting on the sidelines now and a little skeptical about them.
Might take a chance on this
Is this a joke? Lol
1. It's Almost Acquisition Time
As Celsion has been stating and as I've been reporting, the company is almost certainly going to be making some acquisitions as part of its "post-HEAT study corporate strategy". Jeff Church said in their previous conference call that the company had about ten potential candidates for M&A at the time. I pointed this out in a previous article:
Celsion also noted on its conference call that it had significantly cut costs and was working with Cantor Fitzgerald on potential mergers and acquisitions; a step that the company said could bring profitability and give it another leg (aside from ThermoDox) to stand on.
Going into this week, Celsion had plenty of money in the bank; enough to get them well into 2014, with their current burn rate of about a million a month. So, why raise money now? There could be four reasons for doing it right now:
Least likely -- Celsion wants to "strike while the iron is hot" and take advantage of the recent run in the stock price
More likely -- Celsion sees this as a great time to continue to bolster their balance sheet with significantly less dilution than their last financing
More likely -- It's a market strategy move to put a floor on the stock
Very likely -- Celsion is going to be shelling out money soon for something, probably an acquisition
Definition of 'Confidential Treatment Order - CTO'
An order that provides confidential treatment for certain documents and information, that a company would otherwise have to file. A confidential treatment order (CTO) is issued by the Securities and Exchange Commission (SEC) and may only be in effect for a certain period of time, rather than indefinitely.
It wants to move up, but maybe in the last hour it will.
On May 22, 2013, Fuse Science, Inc. (the “Company”) held a business update teleconference and webcast for shareholders and the investment community. In the teleconference and webcast, the Company’s executive officers noted, among other business updates, that:
· sales of the Company’s products for the month of April 2013 exceeded sales for all of the fiscal year ended September 30, 2012; and
· in furtherance of its national distribution strategy, the Company is on schedule to have its PowerFuse® and ElectroFuse® products rolled out into all stores in the Walgreens chain by the end of June 2013 and will begin selected radio advertising on Memorial Day weekend.
0.30?!
Once this is on the Nasdaq, sky is the limit
MusclePharm Executive V.P. and Co-Founder, Cory Gregory, Featured on Cover of July Edition of Fitness Rx Magazine
MusclePharm Corporation (OTCQB: MSLP), a fast growing company that develops and markets sports nutritional supplements which address active lifestyles, announced today its Executive Vice President and co-founder, Cory Gregory, pictured with his three young children, is on the cover of the July 2013 issue of Fitness Rx Magazine for Men. The issue is available nationwide at most drug stores, convenience stores, book stores and newsstands. It is estimated that there are approximately 1,000,000 readers of Fitness Rx for Men.
Steve Blechman, CEO and Chairman of Advanced Research Press, the publisher of FitnessRx for Men, commented, "Cory Gregory made a great cover model for our July 2013 publication and he is living proof that dads and successful entrepreneurs can stay in top shape! Cory is an inspiration to many and it was a pleasure having him and MusclePharm be a big part of the issue. We look forward to working together again moving forward in the future."
The issue features Gregory and MusclePharm in three separate articles, each of which is accented in lime green -- the same color as MusclePharm's unique and eye-catching "MP" logo. There is a sports supplement review titled, "MusclePharm - The 'Bizzy Diet' Stack"; an article titled, "Get Jacked! The 1,000 Rep Workout"; and lastly, an article titled, "The Ultimate Ripped Abs and Diet Workout."
The center of the issue features a large cutout two-sided poster -- one side having a pictorial of Gregory demonstrating his abdominal workout while the other side is a powerfully presented MusclePharm advertisement highlighting three of MusclePharm's leading products: AMINO 1, ASSAULT and SHRED Matrix.
FNMA.OB, FMCC.OB
02:02 PM Bruce Berkowitz has taken about a $500M stake in the preferred stock of Fannie Mae (FNMA.OB -23%) and Freddie Mac (FMCC.OB -23.2%) - please note the symbols here are for the common. "The time to restructure (Frannie) is upon us," he tells CNBC. "Taxpayer dollars ... will be fully repaid ... and equitable treatment of taxpaying shareholders, including community banks and insurance companies must be restored." The common stock has rebounded somewhat from an early plunge, and the preferred shares have turned higher.
If these averages hold up (under 90% payouts), Fannie Mae would be able to pay approximately $4.6 billion per quarter from here on out, and Freddie would be able to pay $3.1 billion. Based on the current level of outstanding bailout debt, this rate would zero out Fannie's liability in just five quarters, and Freddie's in 12 -- in either case, far faster than a reported 10-year timetable for full repayment set by the Obama administration. That's even if you count a hoped-for $50 billion profit, which would take another seven quarters of repayment between the two GSEs.
It should therefore come as no surprise that a number of major hedge funds are now taking up positions in Fannie and Freddie's shares and are lobbying hard for the government to spin off its stake, again making Fannie and Freddie the publicly traded companies they once were. Even erstwhile presidential campaigner (and GSE stockholder) Ralph Nader is up in arms at the government's apparent dalliance over returning a cash cow to private ownership. With at least one writer now claiming that the Federal Housing Finance Agency (the GSEs' conservator) has breached its fiduciary duty to shareholders, it seems likely that the Fannie and Freddie situation must be resolved far sooner than the government had hoped -- quite possibly in court, should Fannie and/or Freddie zero out their debts in the next two years or so.
Thanks to stricter lending requirements, higher fees, and a lack of real competition, Fannie and Freddie appear headed for record profitability, even when discounting the impact of tax charges. We're highly unlikely to see these two enterprises vanish from the American housing picture, considering that the vast majority of American mortgages now bear the Fannie or Freddie guarantee. If they do, there's a massive amount of assets (more than $5 trillion) to be wound down first and thus accrue to shareholders -- though preferred shareholders would get first crack-- another reason why institutional investors like the GSE story right now.
After an incredible rally, the remaining upside in Fannie and Freddie shares will depend largely on how effective large shareholders are in lobbying for the results they want. Fannie and Freddie didn't have the same strident voices in their favor as did the financial industry in 2008. Now they appear to. You might not like Wall Street, but do you really want to bet against it when it smells a good deal?
Why Bank of America Might Lose at This Important Hearing
By Amanda Alix | More Articles | Save For Later
May 28, 2013 | Comments (2)
Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Click Here Now
This is the week that the fate of a distinctly unsettled prior settlement between Bank of America (NYSE: BAC ) and 22 institutional investors gets put to the test in the courtroom of New York State Supreme Court Justice Barbara Kapnick. At issue is a New York law called Article 77, which will be used to answer the question of whether or not Bank of New York Mellon (NYSE: BNY ) , as trustee for the settlement, acted reasonably in accepting the terms on behalf of the complainants.
Certainly, the $8.5 billion settlement amount is big enough to worry about all on its own, but there is another issue here, and for Bank of America, it's huge: Does B of A have successor liability for the bad behavior of Countrywide?
Intertwined with the Article 77 matter
It's a valid question, and it is considered germane to whether BONY acted in a reasonable manner pursuant to the settlement. As BTIG's Mark Palmer has noted, the pact was based upon the notion that B of A did not have successor liability, so revisiting that particular point might throw the whole deal out the window, and cause B of A lots of anguish -- both now and in the future.
Of course, as Alison Frankel muses, Kapnick could take the path of least resistance and endorse the settlement. This would save both B of A and BONY a big hassle, and prevent everybody from having to go back to the starting gate.
But, it probably won't be that easy. The question of successor liability by B of A for Countrywide has come up before, in the recently settled battle between the bank and monoline insurer MBIA (NYSE: MBI ) . Earlier this year, the insurer filed with the New York courts a very long and colorful presentation in its bid to win summary judgment on this very issue. Despite its effort, however, New York State Supreme Court Justice Eileen Bransten wouldn't rule either for or against the question, citing disputed facts that needed more scrutiny. But, in a blow to Bank of America, she did decide that the successor liability issue should be heard in New York, rather than Delaware, which was B of A's preferred venue.
NY AG's case seems to favor a loss for B of A
Kapnick could still decide that there is no such liability on Bank of America's part toward Countrywide, but she would be going up against the Attorney General of New York, who last year filed suit against B of A for $1 billion in damages regarding substandard loans Countrywide sold Fannie Mae and Freddie Mac several years ago.
In the complaint filed in the so-called "Hustle" case, U.S. Attorney Preet Bharara outlines how the state of New York considers Bank of America to be liable for this shoddy behavior -- both as a direct participant, and as the successor to Countrywide. Preet alleges that the two entities engaged in a de facto merger, much as MBIA had -- at least, according to New York law. And, that's what counts at this point.
Will Kapnick approve the settlement without going into all these issues? In its motion to have the Hustle suit dismissed, B of A argued only that the AG's office hadn't proved fraud. For obvious reasons, the question of the bank's responsibility for Countrywide's abuses is one can of worms that B of A would rather not open.
3.90 at close
To relist they need trade for over $4 for 90 days
Actually it began with the Clinton administration and allowing every person in the u.s. to purchase a home with no credit or job. But it continued through the bush administration.
I think I will buy on Tuesday! The housing is gaining strength. I need to hop on this money train!